New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:15 EDTMGNXMacroGenics initiates Phase 1 study of MGD006
MacroGenics announced that a first patient received drug in a Phase 1 study of MGD006 in relapsed or refractory acute myeloid leukemia. MGD006 is a humanized, Dual-Affinity Re-Targeting, or DART, bi-specific antibody-based molecule that binds to both CD123 and CD3, antigens expressed on leukemic cells and T lymphocytes, respectively. This study marks the first clinical trial of a DART product candidate.
News For MGNX From The Last 14 Days
Check below for free stories on MGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
17:20 EDTMGNXMacroGenics IND MGD007 cleared by FDA to start enrolling patients
MacroGenics announced that its investigational new drug, or IND, for MGD007 has been cleared by the FDA to proceed with the phase 1 human clinical trial for this drug candidate. MGD007 is a Dual-Affinity Re-Targeting protein being developed for the treatment of colorectal cancer. MacroGenics will receive a $5M milestone payment from Servier, France's largest privately-held pharmaceutical company, triggered by the IND clearance.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use